SCIENTIFIC ADVISORY BOARD

Professor of Cardiovascular Medicine,

Stanford University.

Prof Euan A. Ashley | BSc (Hons1)

Glasgow | PhD Oxford.

Professor of Medicine (Cardiovascular) at the Stanford University Medical Center.
Young Investigator Award, European Society of Cardiology (2002).
Career Development Award (K08), National Institutes of Health (2006).
Innovative Research Award, American Heart Association (2008).
NIH Director's New Innovator Award, National Institutes of Health (2009).

Professor of Cardiovascular Medicine,

University of Oxford.

Prof Charalambos Antoniades | MD (Hons)

PhD Athens.

Director, Acute Vascular Imaging Centre and Deputy Head, Division of Cardiovascular Medicine.
British Heart Foundation Senior Clinical Fellow and Honorary Consultant Cardiologist.
The Antoniades Group studies the interplay between adipose tissue and the cardiovascular system. The Group also work towards the discovery of new therapeutic targets for the prevention and treatment of cardiovascular diseases.

Strategy, Regs, Tox and CMC

Consultant

Evan Siegel | PhD, BS, MS, M Phil

CEO and President of Ground Zero Pharmaceuticals, Inc.
Principal Regulatory Scientist & Director Regulatory Services, Quintiles, Inc.
Director/Sr. Director, Regulatory Affairs and Corporate Compliance, Syntex, Inc. and Astra Inc.
Reviewing Toxicologist, US FDA; Supervising Toxicologist, California Food and Drug Branch.

External Advisors

Patent Attorneys

Spruson and Ferguson | www.spruson.com

Licensing

Accounting & Audit

COMPANY MANAGEMENT

Managing Director

Jay Hennock | BEc

Sydney

Over 25 years in corporate advisory services with Citibank, Bank of America and Jacanda Capital.
Co-founded Access Systems, sold to International Gaming Technology Inc.
Co-founder and CFO of Nuon Therapeutics Inc. and founder and CEO of Bioatrix Pty Ltd.
Sold Bioatrix to ZZ Biotech LLC and is currently a Director of Novapep and Prokardia.

Senior Researcher

Dr Owen Tang, | PhD.

Dr. Owen Tang is a senior post-doctoral researcher who became a member of the Figtree lab in 2014.
With a background in molecular biology, he successfully earned a PhD in renal medicine.
Dr. Tang's pioneering research primarily revolves around the early detection of cardiovascular diseases in patients.
His expertise is in the intricate field of redox biology, with a specific focus on the redox flux within red blood cells.

Chief Medical Officer, Kardiomics

Prof Gemma Figtree | MBBS (Hons1)

Sydney | DPhil Oxford.

Professor in Medicine at the University of Sydney and interventional cardiologist at the RNSH.
President of the Australian Cardiovascular Alliance, and lead of global consortium CAD Frontiers, working with US FDA towards accepting CT coronary angiography measures of coronary artery disease as validated surrogate for translation of new drugs and diagnostics.
Rhodes Scholar Oxford in the field of oxidative signalling and translational cardiovascular research.
Discoveries in Gemma’s Laboratory have been published in leading journals Circulation, European Heart Journal, JACC and Circulation, with >300 publications in peer-review journals.
Principal investigator on grants (>$25 Mill) from NHMRC, the Heart Foundation, Heart Research Aust.

Operations Manager

Dr Zara Ali | PhD

Operations Manager, Figtree Lab, University of Sydney and Royal North Shore Hospital.
Research Program Manager, Figtree Lab, University of Sydney.
CAD Frontiers Part-time Operations Manager.